483 related articles for article (PubMed ID: 29938545)
1. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.
Ma C; Jairath V; Vande Casteele N
Best Pract Res Clin Gastroenterol; 2019; 38-39():101606. PubMed ID: 31327403
[TBL] [Abstract][Full Text] [Related]
3. Filgotinib for the treatment of Crohn's disease.
Labetoulle R; Paul S; Roblin X
Expert Opin Investig Drugs; 2018 Mar; 27(3):295-300. PubMed ID: 29448862
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.
Cordes F; Foell D; Ding JN; Varga G; Bettenworth D
World J Gastroenterol; 2020 Jul; 26(28):4055-4075. PubMed ID: 32821070
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in crohn's disease: ready to go?
Dell'Avalle C; D'Amico F; Gabbiadini R; Dal Buono A; Pugliese N; Zilli A; Furfaro F; Fiorino G; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Investig Drugs; 2022 Feb; 31(2):145-161. PubMed ID: 35164629
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
7. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
8. JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease.
Macaluso FS; Rodríguez-Lago I
Curr Drug Metab; 2020; 21(4):247-255. PubMed ID: 32156234
[TBL] [Abstract][Full Text] [Related]
9. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
10. JAK selectivity: more precision less troubles.
Roda G; Dal Buono A; Argollo M; Danese S
Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):789-796. PubMed ID: 32520647
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.
Gupta N; Papasotiriou S; Hanauer S
Expert Rev Clin Immunol; 2023; 19(9):1075-1089. PubMed ID: 37226522
[TBL] [Abstract][Full Text] [Related]
12. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
Nakase H
Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials.
Neurath L; D'Amico F; Danese S
Expert Opin Emerg Drugs; 2023 Mar; 28(1):27-42. PubMed ID: 36876333
[TBL] [Abstract][Full Text] [Related]
14. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
Salas A; Hernandez-Rocha C; Duijvestein M; Faubion W; McGovern D; Vermeire S; Vetrano S; Vande Casteele N
Nat Rev Gastroenterol Hepatol; 2020 Jun; 17(6):323-337. PubMed ID: 32203403
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
Ma C; Lee JK; Mitra AR; Teriaky A; Choudhary D; Nguyen TM; Vande Casteele N; Khanna R; Panaccione R; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2019 Jul; 50(1):5-23. PubMed ID: 31119766
[TBL] [Abstract][Full Text] [Related]
16. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD.
Gilardi D; Gabbiadini R; Allocca M; Correale C; Fiorino G; Furfaro F; Zilli A; Peyrin-Biroulet L; Danese S
Expert Rev Gastroenterol Hepatol; 2020 Sep; 14(9):797-806. PubMed ID: 32571107
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of JAK inhibitors in Crohn's Disease.
Rogler G
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S746-S754. PubMed ID: 31781755
[TBL] [Abstract][Full Text] [Related]
18. JAK inhibitors: Novel developments in management of ulcerative colitis.
Fiorino G; D'Amico F; Italia A; Gilardi D; Furfaro F; Danese S
Best Pract Res Clin Gastroenterol; 2018; 32-33():89-93. PubMed ID: 30060943
[TBL] [Abstract][Full Text] [Related]
19. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
20. Review article: emerging drug therapies in inflammatory bowel disease.
Grossberg LB; Papamichael K; Cheifetz AS
Aliment Pharmacol Ther; 2022 Apr; 55(7):789-804. PubMed ID: 35166398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
